Protagonist Therapeutics, Inc Payments of Stock Issuance Costs
Protagonist Therapeutics, Inc (PTGX) reported Payments of Stock Issuance Costs of $25.00 thousand for the 3-month period ending 2022-06-30, per its 10-Q filed 2022-08-04.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2022-08-04
- Protagonist Therapeutics, Inc payments of stock issuance costs for the quarter ending 2022-06-30 was $25.00K.
- Protagonist Therapeutics, Inc payments of stock issuance costs for the quarter ending 2021-03-31 was $148.00K.
- Protagonist Therapeutics, Inc payments of stock issuance costs for the quarter ending 2017-09-30 was $297.00K.
- Protagonist Therapeutics, Inc payments of stock issuance costs for the quarter ending 2016-09-30 was -$770.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2022-06-30 | $25.00K 10-Q · filed 2022-08-04 | $25.00K 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $148.00K 10-Q · filed 2022-05-05 | ||
| 2017-09-30 | $297.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $297.00K 10-Q · filed 2018-11-06 | |
| 2017-06-30 | $0.00 10-Q · filed 2017-08-08 | ||
| 2016-09-30 | -$770.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $0.00 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $770.00K 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |